Table 2.

Samples misclassified by the 5-gene model using FLDA and/or SVM

Sample	FLDA	SVM	PLS3
C010.1.Th1*	0.02 ± 0.29†	0.12 ± 0.04†	0.007
C021.2.Th1‡	-1.40 ± 0.40	-0.03 ± 0.07	0.009
C019.4.UT‡	-0.49 ± 0.27	-0.02 ± 0.05	0.007
C052.1.UT	0.12 ± 0.16†	-0.10 ± 0.03	0.007
C078.1.UT	0.50 ± 0.15†	-0.15 ± 0.03	0.006
C045.1.UT	0.05 ± 0.15†	-0.22 ± 0.03	0.006
S108.1.05	2.73 ± 0.56	-0.04 ± 0.09†	0.033
S161.1.10*	-6.35 ± 0.40†	-0.56 ± 0.05†	0.001
S157.3.15	0.74 ± 0.14	-0.12 ± 0.03†	0.004
S160.1.15*	-2.19 ± 0.33†	-0.25 ± 0.05†	0.075§
S137.1.27*	-1.77 ± 0.25†	-0.16 ± 0.03†	0.001
S142.1.30*	-1.55 ± 0.36†	-0.08 ± 0.08†	0.700§
S156.1.30*	-0.61 ± 0.21†	-0.12 ± 0.04†	0.001
S140.1.39	0.75 ± 0.17	-0.04 ± 0.04†	0.004
S133.1.46*	-1.30 ± 0.21†	-0.15 ± 0.03†	0.002
S130.1.48	-1.78 ± 0.30†	0.10 ± 0.07	0.939§
S159.1.70	0.28 ± 0.10	-0.15 ± 0.03†	0.035
S132.1.84*	-2.31 ± 0.25†	-0.24 ± 0.03†	0.001
S218.1.87*	-0.66 ± 0.20†	-0.44 ± 0.07†	0.218§

Patient samples are sorted by their tumor burden. Columns LDA and SVM contain average scores obtained by these samples ± standard deviation over the approximately 100 times that these samples were tested during 1000 random resamplings. The column labeled PLS3 displays the expression level of PLS3 (in terms of its ratio to the housekeeping gene relative to that in the Stratagene reference RNA sample).

^*Samples that were misclassified by both methods.

^†Scores assigned these samples to incorrect class (positive average scores for controls and negative average scores for patients).

^‡Two control samples, C021.2.Th1 and C019.4.UT, were marginally classified by SVM, even though the average score turned out to be negative, and were considered to be misclassified.

^§Misclassified patients with high levels of PLS3 (with z score more than 5, relative to controls). These high-PLS3 patients may deserve special treatment, because high levels of PLS3 alone are very unusual for healthy individuals.